Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin (Q57825140)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17473846%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

title

Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17473846%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17473846%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Mikko Niemi

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17473846%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

M K Pasanen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17473846%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

H Fredrikson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17473846%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

language of work or name

English

0 references

publication date

2 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17473846%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

30 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17473846%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17473846%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17473846%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

726-733

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17473846%20AND%20SRC:MED&resulttype=core&format=json

Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin

30 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

Statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Transporters and drug therapy: implications for drug disposition and disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Clinical Pharmacokinetics of Atorvastatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Effect of itraconazole on the pharmacokinetics of atorvastatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Pharmacokinetic interactions with rifampicin : clinical relevance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Effect of itraconazole on the pharmacokinetics of rosuvastatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Cyclosporine markedly raises the plasma concentrations of repaglinide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Lipid-lowering response to statins is affected by CYP3A5 polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021

Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100220

7 January 2021